Anzeige
Meldung des Tages: Kupfer-Engpass trifft jetzt auf starke Rohstoffhausse

Teva Pharmaceutical Aktie (ADR) News

Aktie
WKN:  883035 ISIN:  US8816242098 US-Symbol:  TEVA Branche:  Pharmazeutika Land:  Israel
31,81 $
+0,15 $
+0,47%
26,816 € 23.01.26
Depot/Watchlist
Marktkapitalisierung *
31,15 Mrd. €
Streubesitz
39,66%
KGV
-15,52
Dividende
0,071 €
Dividendenrendite
0,26%
Faktor
1
Originalaktie
IL0006290147
neu: Nachhaltigkeits-Score
58 %
Weiter aufwärts? Long handeln - Jetzt mit Hebel 9,16: UQ3RQ1
Werbung

Teva Pharmaceutical Aktie (ADR) News

16.06.25 - GlobeNewswire
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
Teva-​engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-​Teva ...
03.06.25 - GlobeNewswire
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today the pricing and early acceptance ...
03.06.25 - GlobeNewswire
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today the early tender results in connection ...
31.05.25 - GlobeNewswire
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-​quarter are left untreated LTC ...
31.05.25 - GlobeNewswire
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
Real-​world claims studies evaluating UZEDY ® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) ...
29.05.25 - GlobeNewswire
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
Teva outlines acceleration path into a leading biopharma company Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO ® (deutetrabenazine), ...
27.05.25 - GlobeNewswire
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for ...
27.05.25 - GlobeNewswire
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management ...
27.05.25 - GlobeNewswire
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseases BD9 designed using Biolojic’s Multibody Platform, which generates ...
25.05.25 - wallstreetONLINE Redaktion
Neue Favoriten: Multimilliardär Druckenmiller tauscht Nvidia, Amazon & Tesla gegen diese High-Potential-Aktien
Top-​Investor Stanley Druckenmiller kehrt Aktien wie Nvidia, Amazon, Palantir und Tesla den Rücken, während er diese aussichtsreichen Werte aufstockt.Stanley Druckenmiller ...
22.05.25 - GlobeNewswire
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it is increasing the maximum ...
20.05.25 - GlobeNewswire
Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it successfully upsized its offering ...
20.05.25 - GlobeNewswire
Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's ...
19.05.25 - GlobeNewswire
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it has commenced tender offers ...
19.05.25 - GlobeNewswire
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today its intention to issue $2,000,000,000 ...
16.05.25 - GlobeNewswire
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the ...
12.05.25 - GlobeNewswire
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of schedule Teva ...
07.05.25 - GlobeNewswire
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
For an accessible version of this Press Release, please visit www.tevapharm.com
07.05.25 - GlobeNewswire
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on ...
05.05.25 - GlobeNewswire
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
The U.S. FDA has approved SELARSDI ™ ( ustekinumab-​aekn ) as interchangeable with the reference biologic Stelara ® ( ustekinumab ) in all presentations matching the reference ...

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »
Anzeige

Aktie im Fokus

GOLD-AUSBRUCH
GMV Minerals
0,187 €
+13,3%
GMV Minerals Chart
Von der PEA zum Milliarden-Potenzial
Mehr zur Aktie »